GlassScriptPhysician profile
Marilyn G Foreman
NPI 1427058304
$2,919.65
in general payments reported to CMS, 2019-2025
25 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $372 · 2021: $337 · 2022: $256 · 2023: $137 · 2024: $159 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.64 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $386.78 | 2019-2023 | Nucala |
| Janssen Pharmaceuticals, INC | $282.12 | 2021-2022 | |
| Grifols USA, LLC | $228.21 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $215.01 | 2019-2025 | Tezspire, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.78 | 2019-2020 | |
| Mylan Specialty L.P. | $192.73 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $187.04 | 2019-2025 | Dupixent |
| Genzyme Corporation | $167.32 | 2019-2025 | |
| Electromed, INC. | $153.69 | 2019-2021 | |
| United Therapeutics Corporation | $149.51 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $138.43 | 2019-2021 | |
| Abbvie INC. | $122.27 | 2022-2023 | |
| Insmed, INC. | $97.14 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $94.25 | 2019-2024 | Uptravi, Opsumit |
| Philips North America LLC | $68.14 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $35.00 | 2019 | |
| Shire North American Group INC | $31.11 | 2019 | |
| Tempus Ai, INC | $28.80 | 2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $23.24 | 2025 | Keytruda |
| Pulmonx Corporation | $20.12 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Olympus America INC. | $20.08 | 2022 | |
| Optinose US, INC. | $19.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.38 | 2020 | |
| Mallinckrodt Hospital Products INC. | $17.58 | 2020 | |
| La Jolla Pharmaceutical Company | $15.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Foreman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.